New drug aims to break down Alzheimer's brain clumps
NCT ID NCT06182085
Summary
This study is testing whether a new drug called PRI-002 is safe and can help people with early-stage Alzheimer's disease. The drug is designed to break apart harmful clumps of protein in the brain that are thought to cause memory and thinking problems. About 304 people with mild memory issues due to Alzheimer's will receive either the drug or a placebo for 48 weeks to see if it slows their decline.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A-Shine, s.r.o.
Pilsen, 30100, Czechia
-
AOU Policlinico Umberto I
Rome, 00161, Italy
-
ASST Spedali Civili di Brescia
Brescia, 25123, Italy
-
Brain Research Center Amsterdam B.V.
Amsterdam, 1081 GN, Netherlands
-
Brain Research Center Den Bosch B.V.
's-Hertogenbosch, 5223 LA, Netherlands
-
Brain Research Center Zwolle B.V.
Zwolle, 8025 AZ, Netherlands
-
CLINTRIAL, s.r.o.
Prague, 10000, Czechia
-
Charité - Universitätsmedizin
Berlin, 13125, Germany
-
Clinica Neurologica Dipartimento di Neuroscienze e Imaging (CAST)
Chieti, 66013, Italy
-
Euromedis Sp. z o.o., Centrum Medyczne EUROMEDIS
Szczecin, 70-111, Poland
-
FORBELI s.r.o.
Prague, 14800, Czechia
-
Fondazione IRCCS.Istituto Neurologico Carlo Besta
Milan, 20133, Italy
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, 00168, Italy
-
Fundació ACE - Institut Català de Neurociències Aplicades
Barcelona, 08028, Spain
-
Hospital Clínico Universitario Virgen de la Arrixaca
El Palmar, Murcia, 30120, Spain
-
Hospital Universitario Doctor Peset
Valencia, 46017, Spain
-
Hospital Universitario Virgen Macarena,
Seville, 41003, Spain
-
Hospital Viamed Montecanal
Zaragoza, 50012, Spain
-
INEP Medical s.r.o.
Prague, 18600, Czechia
-
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
-
ISPG - Institut für Studien zur Psychischen Gesundheit
Mannheim, 68165, Germany
-
Krakowska Akademia Neurologii Sp. z o.o., Centrum Neurologii Klinicznej
Krakow, 30-505, Poland
-
Neuro Health Centrum ltd.
Brno, 62800, Czechia
-
NeuroCor, ul. Medweciego 7/U12
Krakow, 31-870, Poland
-
Neuroprotect Sp. z o.o., Centrum Medyczne NeuroProtect
Warsaw, 01-684, Poland
-
Neuropsychiatrie s.r.o.
Prague, 16000, Czechia
-
NeuropsychiatrieHK, s.r.o.
Hradec Králové, 50341, Czechia
-
Ospedale Bellaria - IRCCS Istituto delle Scienze Neurologiche
Bologna, 40139, Italy
-
Ospedale Santa Maria della Misericordia
Perugia, 06129, Italy
-
Revit Sp. z o.o., Podlaskie Centrum Psychogeriatrii
Bialystok, 15-756, Poland
-
Technische Universität München
München, 81675, Germany
-
Uniklinik RWTH Aachen
Aachen, 52074, Germany
-
University Medical Center Rostock
Rostock, 18147, Germany
-
Universitätsklinikum Düsseldorf
Düsseldorf, 40225, Germany
-
Universitätsklinikum Magdeburg
Magdeburg, 39120, Germany
-
Universitätsklinikum Münster - Klinik für Allgemeine Neurologie
Münster, 48149, Germany
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
-
Wielospecjalistyczne Centrum Medyczne "Ibismed" s.c.
Zabrze, 41-800, Poland
Conditions
Explore the condition pages connected to this study.